Results 141 to 150 of about 5,158 (194)

Post-marketing surveillance of radium-223 chloride in Japanese patients with castration-resistant prostate cancer with bone metastasis-final analysis of 3-year extended follow-up focusing on bone fractures. [PDF]

Int J Clin Oncol
Masumori N, Hosono M, Takahashi S, Kakehi Y, Uemura H, Sunaya T, Shimotsumagari K, Matsuba Y, Adachi M, Kakiuchi H, Kinuya S.   +10 more
europepmc   +1 more source

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial. [PDF]

J Clin Oncol
Wang JH, Sherry AD, Bazyar S, Sutera P, Radwan N, Phillips RM, Deek MP, Lu J, Dipasquale S, Deville C, DeWeese TL, Song DY, Wang H, Hobbs RF, Malek R, Dudley SA, Greco SC, Antonarakis ES, Marshall CH, Denmeade S, Paller CJ, Carducci MA, Pienta KJ, Oz OK, Ramotar M, Leenstra JL, Park SS, Abramowitz MC, Desai N, Berlin A, Stish BJ, Tang C, Tran PT, Kiess AP.   +33 more
europepmc   +1 more source

Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer. [PDF]

Front Med (Lausanne)
Shore N, Carles J, McDermott R, Agarwal N, Tombal B.   +4 more
europepmc   +1 more source

Treatment outcomes with radium-223 in patients with metastatic castration-resistant prostate cancer with bone metastasis in real-world practice: a multiinstitutional study. [PDF]

Prostate Int
Kitano H, Hashimoto K, Hasegawa Y, Fujita A, Shinmei S, Kirishima F, Shirane S, Asami A, Naito M, Kohada Y, Kobatake K, Sekino Y, Kato M, Kadonishi Y, Mochizuki H, Kajiwara M, Hinata N.   +16 more
europepmc   +1 more source

Racial Differences in Radium-223 Treatment Response and Adverse Effects in a Small-Cohort, Pilot, Hypothesis-Generating Observational Study. [PDF]

Ochsner J
Yang J, Nittala MR, Vijayakumar S, Vijayakumar V.   +3 more
europepmc   +1 more source

Predicting bone marrow suppression from urinal 8-hydroxy-2'-deoxyguanosine level during the treatment with radium-223 in patients with cancer bone metastasis. [PDF]

Transl Cancer Res
Monzen S, Kasai Y, Kinbara R, Suto K, Morino Y, Terada K, Wojcik A, Mariya Y.   +7 more
europepmc   +1 more source

Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer. [PDF]

Front Oncol
Anido-Herranz U, Fernandez-Calvo O, Ruiz-Bañobre J, Martinez-Breijo S, Fernandez-Nuñez N, Nogareda-Seoane Z, Garrido-Pumar M, Casas-Nebra J, Muñiz-Garcia G, Portela-Pereira P, Gomez-Caamaño A, Perez-Fentes DA, Santome-Couto L, Lázaro M, Molina-Diaz A, Medina-Colmenero A, Vazquez-Estevez S.   +16 more
europepmc   +1 more source

Synergistic Activity of DNA Damage Response Inhibitors in Combination with Radium-223 in Prostate Cancer. [PDF]

Cancers (Basel)
Dunne VL, Wright TC, Liberal FDCG, O'Sullivan JM, Prise KM.   +4 more
europepmc   +1 more source

Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study. [PDF]

Br J Cancer
O'Sullivan JM, Heinrich D, Castro E, George S, Dizdarevic S, Baldari S, Essler M, Jong IJ, Lastoria S, Hammerer PG, Tombal B, James ND, Meltzer J, Sandström P, Sartor O.   +14 more
europepmc   +1 more source

Joint Regional Uptake Quantification of Thorium-227 and Radium-223 Using a Multiple-Energy-Window Projection-Domain Quantitative SPECT Method. [PDF]

IEEE Trans Med Imaging
Li Z, Benabdallah N, Laforest R, Wahl RL, Thorek DLJ, Jha AK.   +5 more
europepmc   +1 more source